|
⚲
|
| Keyboard |
| Braidwell LP
✚
|
|
|---|---|
| CRD # | 316988 |
| SEC # | 801-122966 |
| CIK # | 0001920938 |
| AUM | 4,985.0 M (2026-03-31) |
| Employees | 32 (59% Investors, 0% Brokers) |
| Fees | |
| Minimum | |
| Phone | 866-453-3929 |
| Address | One Harbor Point, 2200 Atlantic Street Stamford, CT 06902 |
| Source | [IAPD] [EDGAR] [Website] [LinkedIn] |
| Total AUM ($B) |
|---|
| Fees and Compensation — Form ADV Part 2A (3/31/2026) [Brochure] |
|---|
Item 5: Fees and Compensation Fees Braidwell and/or the General Partner, as applicable, will generally receive asset-based management fees (the “Management Fee”) and an annual performance allocation (described in Item 6, below) (the “Performance Allocation”). The fees and allocations applicable to each Fund are disclosed in the respective Fund’s Governing Documents. Management Fees will generally be paid quarterly in advance. In any partial calendar quarter, the Management Fee will be appropriately pro-rated for the applicable partial period. The Management Fee will be calculated prior to the accrual of any Performance Allocation. Braidwell’s fee schedule is omitted because this brochure is only being delivered to qualified purchasers as defined in the Investment Company Act of 1940, as amended (“Investment Company Act”). Transaction Fees The Funds each bear transaction fees and costs in connection with investing and trading, including brokerage commissions (including options and futures trades), outsourced trading fees, spreads, markups on securities, swaps and forwards, short borrowings and dividends, currency and other hedging costs, interest expenses in respect of margin accounts, repurchase agreements, derivatives and other financing expenses and other similar costs and expenses, without limitation. Please see each Fund’s Governing Documents for additional information concerning fees charged and payable by the respective Fund. The feeder funds, as an investor in master funds, generally bear their pro rata share of these costs and expenses. To the extent investment activities occur at the feeder fund level, the feeder fund will bear such costs and expenses directly. Please see Item 12 for a more detailed description of Braidwell’s brokerage practices. Expenses In addition to compensation payable to Braidwell and the transaction fees described above, each Fund will typically bear its pro rata share of the following types of expenses: (i) fees payable to the administrator, legal, accounting, administrative, auditing, tax preparation and other professional expenses (including the fees and expenses of the General Partner acting in its capacity as partnership representative and the partnership representative of each of the master funds); (ii) the costs and expenses of any errors and omissions insurance, directors and officers liability insurance (including in respect of the members of the Fund Oversight Committee (defined below in Item 11)), professional liability or cyber-security insurance obtained on behalf of the Funds, the General Partner, Braidwell and the Fund Oversight Committee members, as applicable; (iii) any fees or expenses charged by proxy voting, class action recovery and monitoring, tax reclamation service providers or loan servicing services on behalf of the Funds or their investments; (iv) fees and expenses related to due diligence, research and market analysis, including research-related travel expenses (which in the case of air travel will be limited to the cost of commercial airfare), in each case, incurred with respect to potential or existing investments (whether or not consummated), which include data subscription and license-based services, including third-party research, expert networks and similar providers; (v) expenses incurred in connection with the evaluating, sourcing, structuring, financing, originating, acquiring, disposing, operating, holding, monitoring, loan servicing, carrying or valuing of any investment (whether or not consummated), including investment- related travel expenses, the costs and expenses of outside legal counsel, tax advisors, brokers, dealers, finders, asset managers, developers, joint venture partners, consultants, work-out specialists and any “broken deal expenses” and reverse breakup and termination fees; (vi) expenses incurred in connection with the use of any valuation services (including third-party valuation agents) and valuation software or other technology to enhance the valuation process relating to investments; (vii) all expenses related to Bloomberg, FactSet or other data providers and pricing services, as well as expenses related to news, quotations, modeling, statistics and market data; (viii) all expenses related to data sets and data warehouses; (ix) all expenses related to order management systems, portfolio management systems, expenses relating to middle-office services or back-office support services provided by the administrator or another party and related expenses, risk management systems, and other technologies and analytical services, support systems and equipment used in the investment management process or for communications with the administrator and the applicable feeder fund’s custodian (including hardware, software, technology infrastructure related to hardware and software, communications and data), including service provider fees and expenses relating to the implementation of such systems and ongoing maintenance costs; (x) taxes imposed on the Funds as determined by the General Partner in its sole discretion, filing fees and expenses, custodial fees and expenses and bank services fees; (xi) the costs of printing and distributing periodic and annual reports and statements and other communications; (xii) expenses of the continuous offering of interests in the applicable feeder fund and interests in the other feeder funds, including investor related travel expenses (which in the case of air travel will be limited to the cost of commercial airfare) and associated costs, the cost of updating, producing and distributing offering memoranda and other client materials; (xiii) expenses relating to any amendment to the operating agreements of the Funds and the solicitation of any investor consents; (xiv) regulatory and compliance expenses directly related to the Funds (including the Funds’ reasonable share of third-party expenses incurred by Braidwell or the Funds in ... |
| Account Minimums and Types of Clients — Form ADV Part 2A (3/31/2026) [Brochure] |
|---|
Item 7: Types of Clients Braidwell provides investment advisory services to the Funds. Investment advice is provided directly to the Funds and not individually to the investors. Investors in the Funds may include, but are not limited to, high net worth individuals, family offices, fund of hedge funds, endowments, foundations, trusts, charitable organizations, insurance companies, pension plans, sovereign wealth funds and corporate or business entities. Details concerning applicable investor suitability criteria and minimum investment are set forth in the respective Fund Governing Documents and subscription materials. The General Partner maintains discretion to accept less than the minimum investment threshold specified in such documents. Certain of the Funds admit only investors that are “accredited investors” within the meaning set forth in Regulation D under the Securities Act of 1933 and “qualified purchasers” as defined in Section 2(a)(51) of the Investment Company Act. Certain other Funds require investors to meet certain suitability qualifications, such as being both (A) “accredited investors” under SEC Regulation D of the Securities Act of 1933 and (B) “qualified purchasers,” as defined in Section 2(a)(51)(A) of the Investment Company Act. It is anticipated that any future pooled investment vehicle managed by Braidwell will have similar eligibility standards as the Funds. Agreements with Investors Braidwell, the General Partner and the Funds generally do not intend to enter into any side letters or similar agreements (“Side Letters”) with any investor that grant more favorable fee, Performance Allocation, liquidity or transparency terms with respect to a Fund than those set forth in the applicable Fund’s then current private placement memoranda. However, Braidwell, the General Partner and the Funds have entered into Side Letters to address specific legal, regulatory or policy limitations, requirements or obligations applicable to certain investors. Notwithstanding the foregoing, each of the Funds, Braidwell and the General Partner is permitted to enter into Side Letters in certain circumstances subject to the Fund Oversight Committee’s review and confirmation, when applicable. No such agreement will necessarily entitle any other investor to the same terms of investment unless otherwise required by applicable law. |
| Sector | Form 13F Holdings | Value ($B) | |
|---|---|---|---|
| Caris Life Sciences Inc | 0.1 | ||
| Neurocrine Biosciences Inc | 0.1 | ||
| Glaukos Corp | 0.1 | ||
| Xenon Pharmaceuticals Inc | 0.1 | ||
| Magenta Therapeutics Inc | 0.1 | ||
| Edgewise Therapeutics Inc | 0.1 | ||
| iRhythm Technologies Inc | 0.1 | ||
| Nuvalent Inc | 0.1 | ||
| Kodiak Sciences Inc | 0.1 | ||
| CG Oncology Inc | 0.1 | ||
| View All | |||
| Holdings by Sector ($B) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| HF | Braidwell Companion CMV 2024-1 LP | 2024-11-26 | 4.9 M | |
| HF | Braidwell Companion CMV 2024-1 Master Fund LP | 2024-11-26 | 5.1 M | |
| HF | Braidwell Companion CMV Transaction Master Fund LP - 2024-1 Series | 2024-11-26 | 6.4 M | |
| HF | Braidwell Companion CMV US LP - 2024-1 Series | 2024-11-26 | 6.6 M | |
| HF | Braidwell Companion CMV LP | [2021-12-01] | 66.5 M | |
| Filed 2022-04-08 (D) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $500,000 · Remaining Indefinite · Duration One year or less · Net Assets Decline to Disclose | ||||
| HF | Braidwell Companion CMV Master Fund LP | 2021-12-01 | ||
| HF | Braidwell Companion CMV Transaction Master Fund LP - 2023-1 Series | 2021-12-01 | ||
| HF | Braidwell Companion CMV US LP - 2023-1 Series | [2021-12-01] | 63.4 M | |
| Filed 2022-04-08 (D) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $500,000 · Remaining Indefinite · Duration One year or less · Net Assets Decline to Disclose | ||||
| HF | Braidwell Partners LP | [2021-12-01] | 2,865.7 M | 1,889.4 M |
| Filed 2026-02-05 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $5,000,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | Braidwell Partners Master Fund LP | 2021-12-01 | 1,970.4 M | |
| View All | ||||
| AUM Breakdown | Accounts | AUM ($B) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 12 | 5.0 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 12 | 5.0 |
| By Discretionary | ||
| Discretionary | 12 | 5.0 |
| Non-Discretionary | 0 | 0.0 |
| Total | 12 | 5.0 |
| By Non-United States Persons | ||
| Non-United States Persons | 1.7 | |
| United States Persons | 3.3 | |
| Total | 12 | 5.0 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Braidwell LP | Executive Officer | 6 | 2 | |
| Manish Mital | Executive Officer | 6 | 2 | |
| Braidwell GP LLC | Promoter | 6 | 2 | |
| Brian Kreiter | Executive Officer | 6 | 2 | |
| Alexander Karnal | Executive Officer | 5 | 2 | |
| Colin Bettison | Executive Officer | 2 | 1 | |
| Alexander Karal | Executive Officer | 1 | 1 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001920938] | |
| SC 13G | [0001920938] |
| Form 13D/13G Filer | Form 13D/13G Subject | Filed |
|---|---|---|
| Braidwell LP | Surrozen Inc/DE | [2026-02-17] |
| Braidwell LP | DBV Technologies Sa | [2023-02-14] |
| Braidwell LP | Crinetics Pharmaceuticals Inc | [2023-02-14] |
| Braidwell LP | Deciphera Pharmaceuticals Inc | [2023-02-14] |
| Firm Profile (Form ADV) | |
|---|---|
| Serves | Institutional |
| Fund Types | Hedge Fund |
| Comparable Firms | State | AUM |
|---|---|---|
|
Maplelane Capital LLC
✚
|
NY | 5,047.1 M |
|
Platinum Investment Management Limited
✚
|
5,038.5 M | |
|
Kirkoswald Capital Management Limited
✚
|
5,014.3 M | |
|
Finepoint Capital LP
✚
|
MA | 5,010.3 M |
|
Fiera Capital UK Limited
✚
|
4,989.3 M | |
|
Gulf International Bank UK Limited
✚
|
4,982.3 M | |
|
Hound Partners LLC
✚
|
NY | 4,976.9 M |
|
Empyrean Capital Partners LP
✚
|
CA | 4,969.1 M |
|
GSA Capital Partners LLP
✚
|
4,914.2 M | |
|
Advantage Advisers Multi-Manager LLC
✚
|
NY | 4,912.6 M |